Searchable abstracts of presentations at key conferences in endocrinology

ea0090p137 | Pituitary and Neuroendocrinology | ECE2023

The Effect of Dual-release vs Conventional Hydrocortisone on the Metabolic Profile in Secondary Adrenal Insufficiency

Thurmann Jorgensen Nanna , Brun Boesen Victor , Willemoes Borresen Stina , Christoffersen Thea , Rye Jorgensen Niklas , Watt Torquil , Feldt-Rasmussen Ulla , Klose Marianne

Background and aim: The dual-release hydrocortisone Plenadren® has shown promising results of improved cardiovascular and metabolic profiles after treatment of adrenal insufficiency, possibly due to an improved circadian profile of cortisol, but results are ambiguous. Aim: To further investigate the potential effect of dual-release hydrocortisone on the metabolic profile as compared to conventional hydrocortisone in patients with secondary adrenal i...

ea0022p617 | Neuroendocrinology and Pituitary (<emphasis role="italic">Generously supported by Novartis</emphasis>) | ECE2010

Epidemiology of craniopharyngioma in Denmark 1985–2004: a 2% increase in incidence rate per year

Husted Nielsen Eigil , Feldt-Rasmussen Ulla , Poulsgaard Lars , Ostergaard Kristensen Lars , Astrup Jens , Otto Jorgensen Jens , Bjerre Per , Andersen Marianne , Andersen Claus , Jorgensen Jesper , Lindholm Jorgen , Laurberg Peter

Background: Craniopharyngioma may be associated with severe morbidity. Few data exist on incidence rate (IR) and possible changes with time. The epidemiology of craniopharyngioma in Denmark has never been evaluated in detail.Objectives: To review the literature on craniopharyngioma incidence and to study the epidemiology of craniopharyngioma in Denmark during a recent 20-year period.Material and methods: Publications including data...

ea0081p634 | Diabetes, Obesity, Metabolism and Nutrition | ECE2022

Determinants and consequences of nonadherence among patients with type-2-diabetes

Raun Hansen Caroline , Wodschouw Helena Zander , Perrild Hans , Moller Christensen Tomas , Jorgensen Torben , Zander Mette

Objective: To determine the cumulative incidence of nonadherent patients with type-2-diabetes from an outpatient clinic, and to examine determinants and consequences of premature discharge.Research design and methods: A cohort comprising patients with type-2-diabetes referred to a Diabetes Clinic from 2009-2012 was assessed. Patients were categorized as nonadherent if discharged within two years of referral due to nonattendance and/or nonadherence to med...

ea0081ep735 | Pituitary and Neuroendocrinology | ECE2022

Endocrine treatment of anabolic-androgenic steroid induced hypogonadism in males: A pilot study

Christian Bordado Henriksen Hans , Palmstrom Jorgensen Anders , Bjornebekk Astrid , Neupane Sudan Prasad , A. Havnes Ingrid

Background and aims: Non-prescribed use of anabolic-androgenic steroids (AAS) is associated with a wide range of health risks including AAS-induced hypogonadism (ASIH) caused by negative feedback suppression on the hypothalamic-pituitary-gonadal (HPG) axis. Testicular function might be reduced for months up to years after AAS-cessation, increasing the risk of developing fatigue, decreased libido, erectile dysfunction, infertility, sleep disorder, depression and anxiety. There ...

ea0090p412 | Pituitary and Neuroendocrinology | ECE2023

Copeptin levels increase in response to both insulin-induced hypoglycemia and arginine but not to clonidine – data from GH-stimulation tests

Stankovic Jelena , Kristensen Kurt , Birkebaek Niels , Otto Jorgensen Jens , Sondergaard Esben

Background: The differential diagnosis of the polyuria-polydipsia syndrome is challenging. The water-deprivation test is the current gold standard, but the test is cumbersome, and the diagnostic performance is poor. Copeptin, which is a split product of the vasopressin pre-propeptide, appears to be a robust biomarker in the circulation and a promising tool for the diagnosis of patients with polyuria and polydipsia, especially when measured in conjunction with intravenous infus...

ea0063gp136 | Obesity | ECE2019

Administration of a growth hormone bolus down-regulates gene-expression of the g0/g1 switch gene 2 (g0s2) in subcutaneous adipose tissue in healthy, obese men: a randomized, placebo-controlled, cross-over study

Hjelholt Astrid , Jessen Niels , Arlien-Soborg Mai Christiansen , Pedersen Steen Bonlokke , Jorgensen Jenso Otto Lunde

Background: Growth hormone (GH) potently stimulates lipolysis, and after GH exposure, levels of serum free fatty acids (FFAs) increase in a distinct temporal pattern characterized by a 1-hour lag phase and a peak after 3 hours followed by a gradual return to baseline. This effect predominantly operates during fasting and promotes utilization of lipids from adipose tissue (AT) at the expense of glucose and protein. Prolonged fasting also downregulates the expression of the G0/G...

ea0063p1109 | Pituitary and Neuroendocrinology 3 | ECE2019

HPA axis function in patients with clinically non-functioning pituitary adenomas: effects of surgery and risk factors for HPA failure

Kolnes Anders Jensen , Oystese Kristin Astrid , Dahlberg Daniel , Bollerslev Jens , Jorgensen Anders Palmstrom

Introduction: Patients planned for first time surgery for clinically non-functioning pituitary adenoma (NFPA) were included in this prospective study.Aims: – To study the prevalence of hypothalamic-pituitary-adrenal (HPA) axis failure preoperatively and 3 months after surgery for clinically NFPA.– To investigate factors predicting risk of HPA axis failure postoperatively.Hypotheses<p class="abst...

ea0049gp190 | Pituitary &amp; endocrine Tumours | ECE2017

Safety of long-term growth hormone (GH) treatment in adults with GH deficiency (GHD): an analysis from the NordiNet® International Outcome Study

Jorgensen Jens Otto , Popovic-Brkic Vera , Pournara Effie , Pedersen Birgitte , Chudecka Anita , Strasburger Christian

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

ea0049ep63 | Adrenal cortex (to include Cushing's) | ECE2017

Treatment with modified-release hydrocortisone for 6 months: A clinical audit in 15 patients with adrenal insufficiency

Steffensen Charlotte , Andersen Marianne , Feldt-Rasmussen Ulla , Kistorp Caroline , Jorgensen Jens Otto L

Background: Patients with adrenal insufficiency (AI) exhibit increased morbidity, mortality and impaired quality of life (QoL) and conventional hydrocortisone replacement does not mimic the endogenous circadian pattern and may compromise adherence. A modified – release hydrocortisone formulation (Plenadren) for once-daily use is licensed in order to meet these needs.Objective: To audit the effects of treatment change from HC to Plenadren in an out-p...

ea0049ep654 | Obesity | ECE2017

Growth hormone signaling and action in obese versus lean human subjects: evidence of increased hepatic GH sensitivity in obesity

Pedersen Morten Hogild , Bak Ann Mosegaard , Pedersen Steen Bonlokke , Jessen Niels , Moller Niels , Jorgensen Jens O.L.

Context: Obesity is accompanied by blunted GH secretion but relatively normal serum IGF-I levels, which suggests increased GH sensitivity. This, however, remains to be tested at the level of GH signaling in human subjects.Objective: To compare the effects of an acute intravenous GH bolus in obese vs normal weight subjects on GH signaling pathways in adipose and muscle tissue, substrate metabolism and insulin sensitivity.Subjects an...